New Devitalized Freeze-Dried Human Umbilical Cord Amniotic Membrane as an Innovative Treatment of Ocular Surface Defects: Preclinical Results.
Fiche publication
Date publication
septembre 2022
Journal
Journal of functional biomaterials
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GINDRAUX Florelle
Tous les auteurs :
Cognard S, Barnouin L, Bosc J, Gindraux F, Robin MC, Douet JY, Thuret G
Lien Pubmed
Résumé
A preclinical study was performed to investigate the efficacy and safety of a new viral inactivated, devitalized, freeze-dried and gamma-sterilized human umbilical cord amniotic membrane (hUC-AM) for the treatment of deep scleral and corneal defects with or without perforation. Firstly, hUC-AM was investigated on experimental deep sclerectomy in rabbit eyes ( = 12) and compared to autograft ( = 4) on cross section histology. Secondly, hUC-AM was studied on a selected series of uncontrolled cases of corneal defects ( = 18) with or without perforation, in dogs and cats. hUC-AM tolerance, reconstruction of the deep corneal lesion and recovery of the structural aspect of the tissue were followed post-surgery. In experimental deep sclerectomy, histology showed that the hUC-AM was well tolerated and degraded completely in 45 days while allowing an overall quality and kinetic of scleral regeneration, similar to autograft. In the clinical situations, hUC-AM was well tolerated, with ocular inflammatory signs quickly decreasing after surgery. Mean follow-up was 16.40 ± 11.43 months. In 15 out of 18 cases, hUC-AM allowed ocular surface wound healing. The ocular surface was fully reconstructed three months after surgery. This study suggests a good safety and efficacy profile of hUC-AM in the treatment of deep corneal or scleral defect in animals. This new tissue should now facilitate the treatment of severe ocular surface diseases in humans.
Mots clés
corneal healing, deep ocular defect, graft, human umbilical cord amniotic membrane, placenta tissue, sclera regeneration
Référence
J Funct Biomater. 2022 09 13;13(3):